Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market

GBI Research
147 Pages - GBI10525
$4,995.00

Summary

Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow. They include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating lymphomas are more prevalent than leukemias or myeloma. Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.

Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments were based on the growing understanding of the signaling pathways involved in disease pathogenesis. Notable examples include the approval of rituximab in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin’s lymphoma.

Overall, there are 1,207 products in active development in the hematological cancer therapy area. The indications included in this disease cluster are classified under oncology, which is the largest therapy area in terms of pipeline products, consisting of 6,936 drugs in development. Hematological cancer has more active pipeline products than the respiratory and cardiovascular therapy areas, which indicates how active this disease cluster is in terms of product development.

Scope

The hematological cancers market is characterized by commercially successful therapies.
 - Which classes of drug dominate the market?
 - What additional benefits have newly approved therapies brought to the market?
 - How do the leading marketed therapies compare clinically?
The pipeline contains a range of molecule types and molecular targets, with a strong emphasis on targeted therapies, as opposed to chemotherapeutic agents.
 - Which molecular targets appear most frequently in the pipeline?
 - What are the commercial prospects for the most promising late-stage pipeline products?
Hematological cancers clinical trials have an overall attrition rate of 70.3%.
 - What are the failure rates at individual Phases of clinical development?
 - How do leukemia, lymphoma and myeloma compare in terms of clinical trial failure rate?
The hematological cancers market is forecast to rise from a value of $30.7 billion in 2015 to $70.1 billion in 2022, at a CAGR of 12.5%.
 - How much of a role will disease prevalence and new product approvals play in market growth?
 - Will generic competition have a significant impact on the market over the forecast period?
Big pharma hold a notable presence in the market.
 - What are the leading companies in terms of market share?
 - Which companies are forecast to experience the greatest growth in market share?
 - What are the drivers of growth for key companies in the market?
 - How dependent are the key companies on this disease cluster for revenue?
 - Which companies rely heavily on this disease cluster for revenue?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment landscape in hematological cancers.
- Assess the current treatment landscape, with product profiles on prominent marketed therapies, including revenue forecasts.
- Analyze the hematological cancers pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
- Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from hematological cancer products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
- Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

'

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 11
2.1 Therapy Area Introduction 11
2.2 Epidemiology 11
2.2.1 Leukemia 12
2.2.2 Lymphoma 13
2.2.3 Myeloma 14
2.3 Pathophysiology 15
2.3.1 Leukemia 15
2.3.2 Lymphoma 16
2.3.3 Myeloma 18
2.4 Symptoms 20
2.5 Diagnosis 20
2.5.1 Leukemia 20
2.5.2 Lymphoma 21
2.5.3 Myeloma 21
2.6 Prognosis and Survival 22
2.6.1 Survival 25
2.7 Treatment 25
2.7.1 Surgery and Radiation Therapy 26
2.7.2 Stem Cell Transplantation 27
2.7.3 Pharmacological Therapies 27
3 Key Marketed Products 30
3.1 Overview 30
3.2 Rituxan/Mabthera (rituximab) - Roche 31
3.3 Gleevec/Glivec (Imatinib) - Novartis 33
3.4 Revlimid (lenalidomide) - Celgene 35
3.5 Velcade (bortezomib) - Millennium/Takeda/Johnson & Johnson 37
3.6 Sprycel (dasatinib) - Bristol-Myers Squibb/Otsuka Pharmaceutical 38
3.7 Tasigna (nilotinib) - Novartis 39
3.8 Pomalyst (pomalidomide) - Celgene 41
3.9 Vidaza (azacitidine) - Celgene 42
3.10 Kyprolis (carfilzomib) - Onyx/Amgen 43
3.11 Adcetris (brentuximab vedotin) - Seattle Genetics/Millennium 45
3.12 Imbruvica (ibrutinib) - AbbVie/Johnson & Johnson 46
3.13 Conclusion 48
4 Pipeline Landscape Assessment 49
4.1 Overview 49
4.2 Pipeline Development Landscape 49
4.3 Molecular Targets in the Pipeline 52
4.4 Clinical Trials 54
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 54
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 58
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 61
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 64
4.4.5 Conclusion 67
4.5 Multi-scenario Market Forecast to 2023 68
4.5.1 Overall Market Size 68
4.6 Generic Penetration 70
5 Revenue Forecast by Molecular Target 72
5.1 Cancer Immunotherapies/Tumor-Associated Antigen 72
5.2 Signal Transduction 73
5.3 Receptor Tyrosine Kinases and Ligands 73
5.4 Revenue and Market Share Analysis by Company 74
5.4.1 Celgene - Will Revenue Loss Associated with Vidaza, Thalomid and Istodax Impact Celgene’s Position as Market Leader? 78
5.4.2 Roche - Will the Patent Expiry of Rituxan Significantly Diminish Revenues? 79
5.4.3 AbbVie/Pharmacyclics - AbbVie Acquiring Pharmacyclics will Drive AbbVie’s Sales Growth 80
5.4.4 Novartis - Large and Growing Product Portfolio to Maintain Revenue Growth 81
5.4.5 Johnson & Johnson - Imbruvica and Velcade Partnerships to be Predominant Contributors to Revenue Growth 82
5.5 Assessment of Key Pipeline Products 83
5.5.1 Venetoclax (ABT-199) - AbbVie/Roche 83
5.5.2 KTE-C19 - Kite Pharma 84
5.5.3 Selinexor (KPT-330) - Karyopharm Therapeutics 85
5.5.4 Polatuzumab Vedotin (RG-7596) - Roche 86
5.5.5 Tisagenlecleucel-T (CTL-019) - Novartis 87
5.5.6 Midostaurin (PKC-412) - Novartis 88
5.5.7 Conclusion 89
6 Company Analysis and Positioning 90
6.1 Company Landscape 91
6.2 Marketed and Pipeline Portfolio Analysis 92
7 Strategic Consolidations 96
7.1 Licensing Deals 96
7.1.1 Deal by Region, Year and Value 96
7.1.2 Deals by Stage of Development and Value 98
7.1.3 Deals by Molecule Type, Molecular Target and Value 99
7.1.4 Table for Licensing Deals Valued Above $100m 101
7.2 Co-development Deals 103
7.2.1 Deals by Region, Year and Value 103
7.2.2 Deals by Stage of Development and Value 105
7.2.3 Deals by Molecule Type, Mechanism of Action and Value 106
7.2.4 Table for Co-development Deals Valued Above $100m 108
8 Appendix 110
8.1 Bibliography 110
8.2 Table of All Clinical Stage Pipeline Products 115
8.3 Abbreviations 143
8.4 Disease List 145
8.5 Methodology 145
8.5.1 Secondary Research 145
8.5.2 Market Size and Revenue Forecasts 146
8.5.3 Pipeline Analysis 146
8.5.4 Competitive Landscape 146
8.6 Contact Us 147
8.7 Disclaimer 147

1.1 List of Tables
Table 1: Hematological Cancers Therapeutics Market, Global, Epidemiology of Hematological Disease Severity, 2016 11
Table 2: Hematological Cancers Therapeutics Market, Global, Lymphoma, Prognostic Factors, 2016 23
Table 3: Hematological Cancers Therapeutics Market, Global, Multiple Myeloma, Prognostic Factors, 2016 25
Table 4: Hematological Cancers Therapeutics Market, Global, Commonly Used Chemo-Regimens, 2016 28
Table 5: Hematological Cancers Therapeutics Market, Global, Approved Indications for Rituxan, 2016 32
Table 6: Hematological Cancers Therapeutics Market, Global, Approved Indications for Gleevec, 2016 34
Table 7: Hematological Cancers Therapeutics Market, Global, Approved Indications for Revlimid, 2016 35
Table 8: Hematological Cancers Therapeutics Market, Global, Approved Indications for Velcade, 2016 37
Table 9: Hematological Cancers Therapeutics Market, Global, Approved Indications for Sprycel, 2016 38
Table 10: Hematological Cancers Therapeutics Market, Global, Approved Indications for Tasigna, 2016 40
Table 11: Hematological Cancers Therapeutics Market, Global, Approved Indications for Pomalyst, 2016 41
Table 12: Hematological Cancers Therapeutics Market, Global, Approved Indications for Vidaza, 2016 42
Table 13: Hematological Cancers Therapeutics Market, Global, Approved Indications for Kyprolis, 2016 44
Table 14: Hematological Cancers Therapeutics Market, Global, Approved Indications for Adcetris, 2016 45
Table 15: Hematological Cancers Therapeutics Market, Global, Approved Indications for Imbruvica, 2016 47
Table 16: Hematological Cancers Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022 69
Table 17: Hematological Cancers Therapeutics Market, Global, Usage of Generics Across Key Indications, 2016 71
Table 18: Hematological Cancers Therapeutics Market, Global, Forecast Revenue by Company, 2016 75
Table 19: Hematological Cancers Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016 101
Table 20: Hematological Cancers Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2016 108
Table 21: Hematological Cancers Therapeutics Market, Global, Pipeline Products in Clinical Development, 2016 115

1.2 List of Figures
Figure 1: Hematological Cancers Therapeutics Market, Global, Epidemiology Patterns for Leukemia, 2015-2022 12
Figure 2: Hematological Cancers Therapeutics Market, Global, Epidemiology Patterns for Lymphoma, 2015-2022 14
Figure 3: Hematological Cancers Therapeutics Market, Global, Epidemiology Patterns for Myeloma, 2015-2022 15
Figure 4: Hematological Cancers Therapeutics Market, Global, Key Marketed Products and Approved Indications, 2016 31
Figure 5: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Rituxan ($bn), 2006-2022 33
Figure 6: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Gleevec ($bn), 2006-2021 35
Figure 7: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Revlimid ($bn), 2006-2022 36
Figure 8: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Velcade ($bn), 2006-2022 38
Figure 9: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Sprycel ($bn), 2006-2022 39
Figure 10: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Tasigna ($bn), 2008-2022 41
Figure 11: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Pomalyst ($bn), 2013-2022 42
Figure 12: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Vidaza ($bn), 2008-2022 43
Figure 13: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Kyprolis ($bn), 2012-2022 45
Figure 14: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Adcetris ($bn), 2011-2022 46
Figure 15: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Imbruvica ($bn), 2014-2022 47
Figure 16: Hematological Cancers Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 49
Figure 17: Hematological Cancers Therapeutics Market, Global, Pipeline for Hematological Cancers by Stage of Development, Molecule Type and Program Type, 2016 50
Figure 18: Hematological Cancers Therapeutics Market, Global, Pipeline for Key Hematological Cancers by Stage of Development, 2016 51
Figure 19: Hematological Cancers Therapeutics Market, Global, Pipeline for Key Hematological Cancers by Molecule Type, 2016 52
Figure 20: Hematological Cancers Therapeutics Market, Global, Pipeline for Hematological Cancers by Molecular Target, 2016 53
Figure 21: Hematological Cancers Therapeutics Market, Global, Pipeline for Key Hematological Cancers by Molecular Target, 2016 54
Figure 22: Hematological Cancers Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016 55
Figure 23: Hematological Cancers Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016 56
Figure 24: Hematological Cancers Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016 57
Figure 25: Hematological Cancers Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016 58
Figure 26: Hematological Cancers Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016 59
Figure 27: Hematological Cancers Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016 59
Figure 28: Hematological Cancers Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016 60
Figure 29: Hematological Cancers Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016 61
Figure 30: Hematological Cancers Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016 62
Figure 31: Hematological Cancers Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016 62
Figure 32: Hematological Cancers Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016 63
Figure 33: Hematological Cancers Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016 64
Figure 34: Hematological Cancers Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2016 65
Figure 35: Hematological Cancers Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016 65
Figure 36: Hematological Cancers Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016 66
Figure 37: Hematological Cancers Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016 67
Figure 38: Hematological Cancers Therapeutics Market, Global, Market Size ($bn), 2015-2022 68
Figure 39: Hematological Cancers Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015-2022 70
Figure 40: Hematological Cancers Therapeutics Market, Global, Annual Revenue Forecast for Cancer Immunotherapies/Tumor Associated Antigen ($bn), 2015-2022 72
Figure 41: Hematological Cancers Therapeutics Market, Global, Annual Revenue Forecast for Signal Transduction ($bn), 2015-2022 73
Figure 42: Hematological Cancers Therapeutics Market, Global, Annual Revenue Forecast for Receptor Tyrosine Kinase and Ligands ($bn), 2015-2022 74
Figure 43: Hematological Cancers Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022 76
Figure 44: Hematological Cancers Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2015-2022 77
Figure 45: Hematological Cancers Therapeutics Market, Global, Revenue by Product Type, 2015-2022 78
Figure 46: Hematological Cancers Therapeutics Market, Global, Celgene Annual Revenue Forecast ($bn), 2015-2022 79
Figure 47: Hematological Cancers Therapeutics Market, Global, Roche Annual Revenue ($bn), 2015-2022 80
Figure 48: Hematological Cancers Therapeutics Market, Global, AbbVie/Pharmacyclics Annual Revenue ($bn), 2015-2022 81
Figure 49: Hematological Cancers Therapeutics Market, Global, Novartis Annual Revenue ($bn), 2015-2022 82
Figure 50: Hematological Cancers Therapeutics Market, Global, Johnson & Johnson Annual Revenue ($bn), 2015-2022 83
Figure 51: Hematological Cancers Therapeutics Market, Global, Revenue for Venetoclax ($bn), 2015-2022 84
Figure 52: Hematological Cancers Therapeutics Market, Global, Revenue for KTE-C19 ($bn), 2015-2022 85
Figure 53: Hematological Cancers Therapeutics Market, Global, Revenue for Selinexor ($bn), 2015-2022 86
Figure 54: Hematological Cancers Therapeutics Market, Global, Revenue for Polatuzumab Vedotin ($bn), 2015-2022 87
Figure 55: Hematological Cancers Therapeutics Market, Global, Revenue for Tisagenlecleucel-T ($bn), 2015-2022 88
Figure 56: Hematological Cancers Therapeutics Market, Global, Revenue for Midostaurin ($m), 2015-2022 89
Figure 57: Hematological Cancers Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022 90
Figure 58: Hematological Cancers Therapeutics Market, Global, Companies by Type, 2016 92
Figure 59: Hematological Cancers Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Hematological Cancers Specialization, 2016 93
Figure 60: Hematological Cancers Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Hematological Cancers, 2015-2022 94
Figure 61: Hematological Cancers Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Hematological Cancers, Top Five Companies ($bn), 2015-2022 95
Figure 62: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Region, Year and Value, 2006-2016 97
Figure 63: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Indication and Value, 2006-2016 98
Figure 64: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016 99
Figure 65: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Molecule Type and Target, 2006-2016 100
Figure 66: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Region, Year and Value, 2006-2016 104
Figure 67: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Indication, 2006-2016 105
Figure 68: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Stage of Development and Value, 2006-2016 106
Figure 69: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Molecule Type and Target, 2006-2016 107

$4,995.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports